Why the study?
Does an everolimus-eluting bioresorbable vascular scaffold prevent target-lesion failure at 1 year in patients with noncomplex obstructive coronary artery disease compared to an everolimus-eluting cobalt-chromium stent?
Does an everolimus-eluting bioresorbable vascular scaffold prevent target-lesion failure at 1 year in patients with noncomplex obstructive coronary artery disease compared to an everolimus-eluting cobalt-chromium stent?
Everolimus-eluting bioresorbable vascular scaffolds demonstrated noninferiority to everolimus-eluting cobalt-chromium stents for target-lesion failure at 1 year in noncomplex obstructive CAD.
No takes yet. Share an insight, caveat, or question.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“As a clinician, I really want to see that long-term data before switching my practice to BVS because we have been burnt in the past before, switching to newer devices without longer-term data.”
1-year noninferiority supports BVS consideration in noncomplex CAD; extends short-term RCT data but leaves long-term durability open.
Ellis et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: